Results 141 to 150 of about 334,604 (352)

Intestinal Barrier Glycosylation for Gut Physiology and Pathology

open access: yesBarrier Immunity, EarlyView.
ABSTRACT The intestinal barrier is a selective structure that safeguards the body from external threats while permitting nutrient absorption and immune surveillance. It consists of the outer mucus layer, the intermediate layer of intestinal epithelial cells (IECs), and the inner layer of immune cells. The proteins in the mucus layer and within IECs are
Girak Kim, Deji Ye, Yikun Yao, Chuan Wu
wiley   +1 more source

Confocal Endomicroscopy Identifies Loss of Local Barrier Function in the Duodenum of Patients with Crohn's Disease and Ulcerative Colitis

open access: yesInflammatory Bowel Diseases, 2014
L. Lim   +9 more
semanticscholar   +1 more source

Streptozotocin induced hyperglycemia in the axolotl

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Diabetes is a group of diseases characterized by loss of β cell mass and/or function, resulting in hyperglycemia. With no established curative treatment, this has initiated research in β cell regeneration. Current animal models have either limited regenerative capacity (mice) or small size and evolutionary distance from humans ...
Pernille Lajer Sørensen   +2 more
wiley   +1 more source

Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR‐HF2 DZHK05 trial): Sex‐specific outcomes

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Intravenous iron has emerged as a guideline‐recommended therapy in patients with heart failure and iron deficiency, but the potential sex‐related differences in efficacy are unknown. We aimed to assess sex‐specific outcomes in the Intravenous Iron in Patients with Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality
Mahir Karakas   +49 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy